PharmEasy: Difference between revisions
No edit summary |
m Nomadicghumakkad moved page Draft:PharmEasy to PharmEasy: Publishing accepted Articles for creation submission (AFCH 0.9.1) |
(No difference)
| |
Revision as of 02:55, 1 January 2022
 | This article, PharmEasy, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
| This article, PharmEasy, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
Comment: It looks like this is a potentially notable topic, but the draft needs a bit of work before it would be accepted as an article.Sources should support the information in the article. This source currently is placed right after the sentence "API Holdings owns the “PharmEasy” brand and provides the technology that powers the “PharmEasy” application." but the source doesn't mention API holdings at all. "PharmEasy has a doorstep delivery service available across India" is followed by these two sources: [1] and [2]. The first of those doesn't mention doorstop delivery, and the second one is a 121-page report that is not available without a licence, which costs more than $2300(!). Meanwhile, the name "PharmEasy" doesn't need a separate source, so inserting this source immediately after the first word of the draft doesn't make sense. The draft contains very little information, but the sources – those that are available – are in fact fairly informative. Why is none of that in the article? And did the editor who added the sources and moved this draft into mainspace in fact read and evaluate the sources fully? bonadea contributions talk 16:31, 14 December 2021 (UTC)
- Comment: See also Draft:Pharmeasy. bonadea contributions talk 11:20, 3 August 2021 (UTC)
PharmEasy is an Indian healthcare app for consumers involved in selling online medicines, diagnostics, telehealth, online doctor consultation services.[1]The company was founded by Dharmil Sheth and Dr Dhaval Shah in 2014[2] and works on a marketplace-based model. PharmEasy is headquartered in Mumbai.[3]
Merger and Competition
In 2020, PharmEasy merged with API Holding, the parent company.[4] Pharmeasy acquired Medlife[5] in 2021.[6] In 2021, the company was also reported to be acquiring Thyrocare.[4] Pharmeasy competes with other players like 1mg, Netmeds and Lifecare.[7]The Ken questioned the brand's positioning as a unified health tech player and referred to its story as more confusing than convincing.[1]
Ad Controversy
One of the Pharmeasy ads garnered controversy in which the company was enacting the Sanjeevani Booti incident from Ramayan.[8]
References
- ^ a b "PharmEasy's theory of healthtech: Unified or confused?". The Ken. 2021-10-05. Retrieved 2021-12-11.
- ^ "IIDE Research of PharmEasy".
{{cite web}}: CS1 maint: url-status (link) - ^ "Frost Research Link" (PDF).
{{cite web}}: CS1 maint: url-status (link) - ^ a b "PharmEasy: A tryout's journey through tests to the Thyrocare takeover". cnbctv18.com. 2021-06-27. Retrieved 2021-12-15.
- ^ "Indian E-Pharmacies: Clash of Titans | BusinessBar". 2021-05-14. Retrieved 2021-12-11.
- ^ May 26, John Sarkar / TNN /; 2021; Ist, 06:55. "Pharmeasy Medlife acquisition: PharmEasy buys Medlife, to be no. 1 e-health entity | India Business News - Times of India". The Times of India. Retrieved 2021-12-15.
{{cite web}}:|last2=has numeric name (help)CS1 maint: numeric names: authors list (link) - ^ "PharmEasy analysymason Link" (PDF).
{{cite web}}: CS1 maint: url-status (link) - ^ "#NoDramaOnlyMedicines doesn't go as planned for PharmEasy". www.adgully.com. Retrieved 2022-01-01.